News-Medical.net - "NIH-Sponsored Comparative Trial Evaluates Benefits of Combination Therapy and Monotherapy In MS"
People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center. The findings, part of the largest-ever MS trial sponsored by the National Institutes of Health, are published in the March 11 issue ofAnnals of Neurology. "This is the first NIH-sponsored, multi-center, comparative trial evaluating the benefits of both combination therapy and monotherapy in MS," said lead author Fred Lublin, MD, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at The Mount Sinai Medical Center.
- Dr. Fred Lublin, Professor, Neurology, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, The Mount Sinai Medical Center